ERBB2 and neoplasm: In addition, in four tumor types with an MSI incidence greater than 1%, HER2 mutation was positively associated with MSI incidence in all these tumors (p<0.05), while HER2 amplification had an opposite effect (Supplementary Figure S7 and Tables S1, S2).